Last reviewed · How we verify
Thyroid hormone
Thyroid hormone replaces or supplements endogenous thyroid hormones (T3 and T4) to restore normal metabolic function in hypothyroid patients.
Thyroid hormone replaces or supplements endogenous thyroid hormones (T3 and T4) to restore normal metabolic function in hypothyroid patients. Used for Hypothyroidism, Thyroid cancer suppression therapy, Myxedema coma.
At a glance
| Generic name | Thyroid hormone |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Thyroid hormone replacement |
| Target | Thyroid hormone receptors (TR-alpha, TR-beta) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Thyroid hormones (levothyroxine/T4 and liothyronine/T3) bind to thyroid hormone receptors in target tissues, increasing metabolic rate, oxygen consumption, and heat production. These hormones regulate protein synthesis, carbohydrate metabolism, and lipid metabolism throughout the body. Replacement therapy restores normal thyroid function in patients with insufficient endogenous hormone production.
Approved indications
- Hypothyroidism
- Thyroid cancer suppression therapy
- Myxedema coma
Common side effects
- Tachycardia
- Palpitations
- Tremor
- Anxiety
- Insomnia
- Heat intolerance
- Weight loss
- Headache
Key clinical trials
- Natural History of Thyroid Function Disorders
- Polycystic Ovary Syndrome in Type 1 Diabetes
- PRESS -PAR: Early Detection and PREvention of Symptomatic postSurgical hypoPARathyroidism After Thyroid Surgery" (NA)
- Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer (PHASE2)
- Frequency of Fibromyalgia Syndrome in Elderly Patients Aged 80 and Above and Its Relationship With Geriatric Parameters
- Novel Approaches to the Treatment of Hypothyroidism (PHASE2, PHASE3)
- A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) (PHASE2)
- Association Between Serum Thyroid-stimulating Hormone (TSH) and Intracytoplasmic Sperm Injection (ICSI) Outcome in Women Undergoing ICSI
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Thyroid hormone CI brief — competitive landscape report
- Thyroid hormone updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI